7th DIA Cardiac Safety Workshop in Japan

It will be a unique opportunity to learn of and discuss the current state and future directions of CV risk assessments and how to prepare for a new regulatory paradigm.

戻る Agenda

[Session 3] Abstract Session 1

Session Chair(s)

Naoki Furuyama, DVM, PHD

Medical Information & Communication, Japan Medical Affairs, Takeda Pharmaceutical Company Limited, Japan

Yuji Kumagai, MD, PHD

Professor, Kitasato Clinical Research Center, Kitasato University Hospital, Japan

Speaker(s)

Can we rely on automated ECG machine measurements for clinical trial decisions?

Chief Medical Officer and Vice President, Global Cardiology, ERT, United States

Heart Rate Correction When the Drug Affects Heart Rate

Statistical Consultant, Statistik Georg Ferber GmbH, Switzerland

Intensive QT investigation as standard practice in early clinical programs

Executive Director, Clinical Pharmacology Science, Deep Human Biology Learning, Eisai, Japan

Evaluation of a proposed novel biomarker, the JTpeak interval, for evaluation of proarrhythmic liability

Chief Scientific Officer, Cardiac Safety, Clario, Sweden

Influence of Food on QT, J-Tpeak and Tpeak - Tend Intervals

Chief Executive Officer, Richmond Pharmacology, United Kingdom